Clinical Use of Non-Invasive Preimplantation Genetic Testing – A Joint Position Statement from the Indian Society for Assisted Reproduction, Indian Fertility Society and Academy of Clinical Embryologists

The Indian Society for Assisted Reproduction (ISAR), Indian Fertility Society (IFS) and Academy of Clinical Embryologists (ACE) jointly recommend that non-invasive preimplantation genetic testing (niPGT) (whether using spent culture media or blastocoel fluid) should not be used in clinical practice at this time and does not recommend it for embryo ranking or selection for transfer in its present form. It has based this position statement on the following key considerations. (1) Diagnostic Accuracy: Current evidence indicates significant error rates, including unacceptably high false positives and false negatives, which undermine its reliability for clinical decision-making. (2) Clinical Efficacy: There is a lack of conclusive evidence that niPGT improves clinical outcomes such as implantation rates, pregnancy rates or live birth rates. The IFS, ISAR and ACE urge the medical and scientific communities to focus on research on niPGT to ensure its reliability and clinical applicability in the future.